These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25936253)

  • 1. Chronic manganism: A long-term follow-up study with a new dopamine terminal biomarker of 18F-FP-(+)-DTBZ (18F-AV-133) brain PET scan.
    Huang CY; Liu CH; Tsao E; Hsieh CJ; Weng YH; Hsiao IT; Yen TC; Lin KJ; Huang CC
    J Neurol Sci; 2015; 353(1-2):102-6. PubMed ID: 25936253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
    Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT
    Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
    Lin SC; Lin KJ; Hsiao IT; Hsieh CJ; Lin WY; Lu CS; Wey SP; Yen TC; Kung MP; Weng YH
    J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
    Hsiao IT; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Lin KJ
    JAMA Neurol; 2014 Jun; 71(6):758-66. PubMed ID: 24756323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson's disease patients.
    Hsiao IT; Weng YH; Lin WY; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lu CS; Lin KJ
    Nucl Med Biol; 2014 Apr; 41(4):322-9. PubMed ID: 24503330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.
    Okamura N; Villemagne VL; Drago J; Pejoska S; Dhamija RK; Mulligan RS; Ellis JR; Ackermann U; O'Keefe G; Jones G; Kung HF; Pontecorvo MJ; Skovronsky D; Rowe CC
    J Nucl Med; 2010 Feb; 51(2):223-8. PubMed ID: 20080893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
    Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
    Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [
    Weng CC; Huang SL; Chen ZA; Lin KJ; Hsiao IT; Yen TC; Kung MP; Wey SP; Hsu CH
    Ann Nucl Med; 2017 Aug; 31(7):506-513. PubMed ID: 28451991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent.
    Lin KJ; Weng YH; Wey SP; Hsiao IT; Lu CS; Skovronsky D; Chang HP; Kung MP; Yen TC
    J Nucl Med; 2010 Sep; 51(9):1480-5. PubMed ID: 20720042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative study of
    Jung Lung H; Weng YH; Wen MC; Hsiao IT; Lin KJ
    Sci Rep; 2018 Oct; 8(1):16027. PubMed ID: 30375444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deuterated
    Liu F; Choi SR; Zha Z; Ploessl K; Zhu L; Kung HF
    Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
    Davis MR; Votaw JR; Bremner JD; Byas-Smith MG; Faber TL; Voll RJ; Hoffman JM; Grafton ST; Kilts CD; Goodman MM
    J Nucl Med; 2003 Jun; 44(6):855-61. PubMed ID: 12791810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging of VMAT2 binding sites in the brain by (18)F-AV-133: the effect of a pseudo-carrier.
    Zhu L; Qiao H; Lieberman BP; Wu J; Liu Y; Pan Z; Ploessl K; Choi SR; Chan P; Kung HF
    Nucl Med Biol; 2012 Oct; 39(7):897-904. PubMed ID: 22749185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
    Weng CC; Chen ZA; Chao KT; Ee TW; Lin KJ; Chan MH; Hsiao IT; Yen TC; Kung MP; Hsu CH; Wey SP
    PLoS One; 2017; 12(3):e0173503. PubMed ID: 28257461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of binding sites for 9-fluoropropyl-(+)-dihydrotetrabenazine ([¹⁸F]AV-133) in a MPTP-lesioned PD mouse model.
    Chao KT; Tsao HH; Weng YH; Hsiao IT; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lin KJ
    Synapse; 2012 Sep; 66(9):823-31. PubMed ID: 22623146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
    Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
    Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of
    Li S; Lu W; Yan S; Song T; Zhang C; Yang C; Lu J
    Quant Imaging Med Surg; 2024 Oct; 14(10):7406-7419. PubMed ID: 39429607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
    Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
    Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ¹⁸F-FP-(+)-DTBZ positron emission tomography detection of monoaminergic deficient network in patients with carbon monoxide related parkinsonism.
    Chang CC; Hsiao IT; Huang SH; Lui CC; Yen TC; Chang WN; Huang CW; Hsieh CJ; Chang YY; Lin KJ
    Eur J Neurol; 2015 May; 22(5):845-52, e59-60. PubMed ID: 25690304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.